Zevra Therapeutics, Inc.
ZVRA
$8.21
-$0.12-1.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 161.81% | 46.47% | -14.02% | 47.85% | 43.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.81% | 46.47% | -14.02% | 47.85% | 43.21% |
| Cost of Revenue | 239.77% | 286.28% | 241.33% | 651.86% | 430.47% |
| Gross Profit | 140.32% | 25.56% | -35.96% | 10.36% | 19.21% |
| SG&A Expenses | 66.06% | 70.75% | 56.51% | 116.67% | 89.05% |
| Depreciation & Amortization | 66.20% | 174.87% | 707.64% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.31% | 32.36% | 43.53% | 84.40% | 91.01% |
| Operating Income | 19.24% | -25.53% | -75.40% | -98.23% | -113.59% |
| Income Before Tax | 132.11% | -52.50% | -95.75% | -355.42% | -312.64% |
| Income Tax Expenses | 10,494.35% | 50,272.73% | -- | -100.00% | -65.23% |
| Earnings from Continuing Operations | 103.96% | -86.01% | -129.13% | -339.38% | -301.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.96% | -86.01% | -129.13% | -339.38% | -301.09% |
| EBIT | 19.24% | -25.53% | -75.40% | -98.23% | -113.59% |
| EBITDA | 23.97% | -19.41% | -65.88% | -87.82% | -107.30% |
| EPS Basic | 89.26% | -47.44% | -75.89% | -252.14% | -247.85% |
| Normalized Basic EPS | 20.39% | -22.36% | -51.20% | -256.67% | -253.72% |
| EPS Diluted | 87.53% | -47.79% | -76.24% | -252.90% | -248.78% |
| Normalized Diluted EPS | 20.77% | -22.36% | -51.20% | -256.67% | -253.72% |
| Average Basic Shares Outstanding | 33.76% | 32.29% | 30.43% | 23.70% | 14.38% |
| Average Diluted Shares Outstanding | 34.74% | 32.29% | 30.43% | 23.70% | 14.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |